<a href="https://www.fiercebiotech.com/biotech/novartis-always-looking-further-ways-shuttle-drugs-brain-despite-run-deals" hreflang="en">Novartis ‘always looking’ for further ways to shuttle drugs to brain despite run of recent deals</a>
Novartis is actively exploring innovative methods to transport drugs across the blood-brain barrier, having recently invested in multiple collaborations, including a $165 million deal with SciNeuro Pharmaceuticals for an Alzheimer's treatment. The company aims to enhance its capabilities in addressing neurodegenerative diseases by leveraging technologies like transferrin receptor (TFR) modulation and remains open to additional partnerships and solutions in this field.
Novartis is actively pursuing multiple avenues to traverse the blood-brain barrier, a crucial challenge in treating neurodegenerative diseases. Their strategic investments in technologies like transferrin receptor (TFR) tuning, combined with partnerships such as those with SciNeuro, Arrowhead, and Sironax, highlight significant opportunities for healthtech professionals to explore collaborative ventures or investments in innovative blood-brain barrier solutions. This approach of diversifying methods to cross the barrier underscores a growing trend in making neurotherapeutics more accessible and effective.